Skip to main content

Enzo Biochem's Q1 Revenues Rise 2 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today reported that its first-quarter 2011 revenues increased 2 percent as increased sales for its clinical labs business offset lower revenues for its life sciences unit.

The New York-based research products and testing firm brought in total revenues of $25.7 million for the three-month period ended Oct. 31, compared to revenues of $25.2 million for the first quarter of fiscal 2010.

Revenues for the Enzo Clinical Labs jumped 12 percent year over year to $12.4 million from $11.1 million, while product revenues, royalties, and license fees for Enzo Life Sciences declined 6 percent to $13.3 million from $14.1 million.

Enzo Biochem's net loss fell to $1.1 million, or $.03 per share, from $1.8 million, or $.05 per share, year over year.

The firm's R&D spending for Q1 was down 28 percent to $1.8 million, and its SG&A spending decreased 4 percent to $11 million.

Enzo finished the quarter with $31.6 million in cash, cash equivalents, and short-term investments.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.